Cylene Pharmaceuticals, Inc. was founded to develop targeted small-molecule drugs to treat life-threatening cancers. The company’s lead drug was CX-3543, which was developed through Phase II clinical trials.
Research Corporation Technologies
Mitsui & Co. Venture Partners
Morningside Venture Investments
William Harris Investors
The Viterbi Group
Laurence Hurley, Ph.D., D.Sc.
University of Arizona (Hurley discovered and initially developed the Cylene technologies while at the University of Texas at Austin)